Skip to main content

Table 3 Overall- and progression-free survival in study arms

From: Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study

 

Gemcitabine

Gemcitabine+nab-P

Overall

HR*

95% CI

p

Median Overall Survival (mo)

5.95

9.92

8.02

0.642

0.422–0.866

0.038

Median Progression-free Survival (mo)

3.22

6.28

4.60

0.582

0.391–0.866

0.008

  1. *Age-adjusted HR for Gemcitabine vs. Gemcitabine + Nab-P  arm
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us